Inhibition of ADP-Induced Platelet Aggregation by Dipyrone in Patients with Acute Myocardial Infarction
Itzhak Weinberger
The Clinical Laboratory, The Israel and lone Massada Center for Heart Diseases, Department of Medicine B, Beilinson Medical Center, Petah-Tikva and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
,
Henry Joshua
The Clinical Laboratory, The Israel and lone Massada Center for Heart Diseases, Department of Medicine B, Beilinson Medical Center, Petah-Tikva and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
,
Jacov Friedmann
The Clinical Laboratory, The Israel and lone Massada Center for Heart Diseases, Department of Medicine B, Beilinson Medical Center, Petah-Tikva and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
,
Saadia Rahamim
The Clinical Laboratory, The Israel and lone Massada Center for Heart Diseases, Department of Medicine B, Beilinson Medical Center, Petah-Tikva and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
,
Jacob Agmon
The Clinical Laboratory, The Israel and lone Massada Center for Heart Diseases, Department of Medicine B, Beilinson Medical Center, Petah-Tikva and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
ADP induced platelet aggregation was investigated in 48 patients within three days of the first signs of acute myocardial infarction (AMI). Thirty six of them received 1 gram of dipyrone. Twelve patients who did not receive dipyrone served as controls.
Platelet aggregation was found severely inhibited in 11 patients who had received dipyrone up to 12 hours before investigation and moderately inhibited among 25 patients who were given the drug 12-24 hours prior to the investigation.
All the patients with AMI who did not receive dipyrone, exhibited a state of hyper- aggregability evidenced by the presence of a second phase of aggregation even with 0.5 μM ADP.
The inhibitory activity of dipyrone on the second phase of platelet aggregation resembles that of other non steroidal anti-inflammatory drugs.
References
1
The Anturane Reinfarction Trial. The Anturane Reinfarction Trial Research Group.
1978; Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. New England Journal of medicine 298: 289
2
Baele G,
Tfflery M,
Vermenlan A,
Barbier F.
1976; Inhibitory effect of ASA on human platelet function in normal volunteers and in women using a combined oral contraceptive regime. Thrombosis and Haemostasis 36: 623
8
Elwood PC,
Cochrane AL,
Burr ML,
Sweetnam PM,
Williams G,
Welsby E,
Hughes SJ,
Renton R.
1974; A randomized controlled trail of Acetyl Salicylic Acid in the secondary prevention of mortality from myocardial infarction. British Medical Journal 1: 436
9
Genton E,
Gent M,
Hirsh H,
Harker LA.
1975; Platelet inhibiting drugs in the prevention of thrombotic disease. New England Journal of Medicine 293: 1174
12
Haft JI,
Gershengorn K,
Kranz DP,
OESTREICHER R.
1972; Protection against epinephrine induced myocardial necrosis by drugs that inhibit platelet aggregation. American Journal of Cardiology 30: 838
14
Massini P,
Luscher EF.
1971; The induction of the release reaction in human blood platelet by close cell contact. Thrombosis et Diathesis Haemorrhagica 25: 13
17
Rossi EC.
1974. The search for a clinically useful inhibitor of primary ADP induced platelet aggregation. In
Caprino L,
Rossi EC.
eds
Platelet aggregation and drugs. Academic Press; p 221
18
Sano T,
Boxer MG J,
Boxer LA,
Yokoyama M.
1971; Platelet sensitivity to aggregation in normal and diseased groups. A method for assessment of platelet aggregability Thrombosis et Diathesis Haemorrhagica 25: 524
22
Zahavi J,
Dreyfuss F.
1969; An abnormal pattern of adenosine diphosphate induced platelet aggregation in acute myocardial infarction. Thrombosis et Diathesis Haemorrhagica 21: 76